Absence of toxicity in patients with malignant otitis externa following long-term treatment with high dosage tobramycin.

Article Details

Citation

Copy to clipboard

Ioannides-Demos LL, Li SC, Bastone EB, Spelman DW, Hooper RE, Cousins VC, McLean AJ

Absence of toxicity in patients with malignant otitis externa following long-term treatment with high dosage tobramycin.

J Antimicrob Chemother. 1994 Aug;34(2):267-74.

PubMed ID

7814288 [ View in PubMed

]

Abstract

An in-vitro model of aminoglycoside dosing was used to demonstrate that the bactericidal activity of tobramycin against Pseudomonas aeruginosa is directly related to the peak concentration of the drug. In addition, six patients who were being treated for malignant otitis externa with long-term, high dosage tobramycin were monitored for oto- and nephro-toxicity; the only adverse effects were transient increases in the serum creatinine concentration in two patients.

DrugBank Data that Cites this Article

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Tobramycin	Approved Investigational	Creatinine	increased	Tobramycin increases the level of Creatinine in the blood